A huge international team has just completed the largest study ever on how our genes control the levels of proteins circulating in our blood. The work, led by researchers at Queen Mary University of London and the Berlin Institute of Health, brings together data from more than 78,000 people across 38 cohorts worldwide and has […]
Radioligand therapy transformed advanced prostate cancer care with PSMA targeting. Now experts eye options for PSMA-resistant or low-expression cases. At APCCC 2026, Dr. Ken Herrmann named ACP3, B7-H3, and STEAP1/STEAP2 as top priorities. These could reach patients (outside clinical trials) in four to five years. ACP3, or prostatic acid phosphatase, binds tighter than PSMA in […]
AKY-2519, a miniprotein radioconjugate targeting B7-H3, has entered a Phase 1b clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The open-label study enrolls both PLUVICTO-naïve and PLUVICTO-experienced patients at multiple U.S. radioligand therapy centers, evaluating three dose levels in each cohort before expanding at selected doses. Preliminary safety and efficacy data from this […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! This week I selected the studies I’ll be following during the ASCO 2026 annual meeting, which will take place at the end of the month. There are some very interesting things! But for now, let’s start with this week’s […]
GX-BP1, a bioPROTAC-based SOX2 degrader, selectively targets SOX2, an undruggable protein, for ubiquitin-proteasome elimination, overcoming limitations of prior inhibition strategies. In preclinical models, GX-BP1 monotherapy delivered approximately 70% tumor growth inhibition, while combinations with agents like carboplatin/paclitaxel achieved 87-96% inhibition and near-complete tumor suppression at optimal doses. Notably, GX-BP1 paired with osimertinib eradicated cancer stem […]
TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is emerging as a next-generation PSMA-targeted radioligand therapy designed to deliver radiation more precisely to prostate cancer cells while limiting exposure to healthy organs. New data from the OPTIMAL-PSMA trial suggest that the drug may achieve strong tumor uptake with relatively low dose to the salivary glands and kidneys, two of the main […]
HS-20093 has received Breakthrough Therapy designation from China’s National Medical Products Administration for metastatic castration-resistant prostate cancer. The designation covers patients previously treated with novel endocrine therapy and taxane-based chemotherapy, a setting where later-line treatment options remain limited. HS-20093 is a B7-H3-targeted antibody-drug conjugate designed to bind tumor cells expressing B7-H3 and deliver a cytotoxic […]
A 2026 study published in Clinical Cancer Research has pinpointed B7-H3 as a standout therapeutic target for prostate cancer, offering hope against the disease’s toughest forms. The work analyzed tissue from prostate cancer patients across the full spectrum, from hormone-sensitive and castration-resistant to neuroendocrine and “double-negative” subtypes, revealing B7-H3’s consistent, broad expression. This uniformity stands […]
A new clinical trial has recently begun for a promising but complex type of cancer treatment called BPX-601, designed specifically for men dealing with advanced prostate cancer that has stopped responding to traditional therapies. This therapy is a form of CAR T-cell treatment, which means doctors take a patient’s own immune cells, reprogram them in […]
Prostate cancer treatments have hit a wall with castration-resistant cases, where tumors keep growing despite hormone blockers targeting the androgen receptor’s stable parts. A new study from University of British Columbia and BC Cancer researchers published on Nature cracks that open by hitting the receptor’s “undruggable” intrinsically disordered transactivation domain (NTD/TAD), the flexible region that […]